PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NovoCure Limited (NVCR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

JE00BYSS4X48

CUSIP

852387208

Sector

Healthcare

IPO Date

Oct 2, 2015

Highlights

Market Cap

$3.44B

EPS (TTM)

-$1.39

PEG Ratio

-0.47

Total Revenue (TTM)

$577.74M

Gross Profit (TTM)

$441.47M

EBITDA (TTM)

-$132.87M

Year Range

$11.70 - $34.00

Target Price

$35.00

Short %

6.22%

Short Ratio

6.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
NVCR vs. GSG NVCR vs. GSGDX NVCR vs. MRK NVCR vs. VOO NVCR vs. COST NVCR vs. MELI
Popular comparisons:
NVCR vs. GSG NVCR vs. GSGDX NVCR vs. MRK NVCR vs. VOO NVCR vs. COST NVCR vs. MELI

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in NovoCure Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%200.00%JulyAugustSeptemberOctoberNovemberDecember
68.49%
203.93%
NVCR (NovoCure Limited)
Benchmark (^GSPC)

Returns By Period

NovoCure Limited had a return of 106.30% year-to-date (YTD) and 130.71% in the last 12 months.


NVCR

YTD

106.30%

1M

82.68%

6M

61.51%

1Y

130.71%

5Y*

-18.78%

10Y*

N/A

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of NVCR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-6.76%9.99%2.09%-21.69%79.82%-22.17%32.92%-14.62%-19.60%-2.88%32.02%106.30%
202324.31%-15.58%-21.87%9.58%8.97%-42.21%-21.35%-32.41%-26.79%-17.65%-7.74%21.68%-79.65%
2022-8.56%19.24%1.21%-7.57%4.96%-13.54%-2.17%20.80%-7.49%-7.00%8.75%-4.54%-2.30%
2021-6.98%-7.37%-11.35%54.41%-0.05%8.74%-30.57%-12.86%-13.44%-11.71%-8.71%-19.82%-56.61%
2020-3.33%-10.69%-7.44%-2.29%2.48%-12.06%27.81%9.18%34.51%9.69%2.91%37.72%105.34%
201946.36%9.61%-10.31%-8.51%20.54%19.03%31.61%9.18%-17.70%-4.20%28.67%-8.58%151.70%
201811.14%-8.46%6.08%25.23%15.20%-0.48%8.63%32.50%16.32%-36.76%3.56%-2.45%65.74%
2017-19.11%19.69%6.58%39.51%11.06%37.85%19.08%-0.49%-3.17%8.82%-10.88%4.94%157.32%
2016-44.19%-6.33%23.87%-10.91%-13.72%4.85%-35.56%2.13%11.20%-29.16%28.10%1.29%-64.89%
201522.92%8.37%-8.17%22.32%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 87, NVCR is among the top 13% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of NVCR is 8787
Overall Rank
The Sharpe Ratio Rank of NVCR is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of NVCR is 9090
Sortino Ratio Rank
The Omega Ratio Rank of NVCR is 8686
Omega Ratio Rank
The Calmar Ratio Rank of NVCR is 8787
Calmar Ratio Rank
The Martin Ratio Rank of NVCR is 8686
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for NovoCure Limited (NVCR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for NVCR, currently valued at 1.58, compared to the broader market-4.00-2.000.002.001.582.10
The chart of Sortino ratio for NVCR, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.002.782.80
The chart of Omega ratio for NVCR, currently valued at 1.31, compared to the broader market0.501.001.502.001.311.39
The chart of Calmar ratio for NVCR, currently valued at 1.46, compared to the broader market0.002.004.006.001.463.09
The chart of Martin ratio for NVCR, currently valued at 6.54, compared to the broader market-5.000.005.0010.0015.0020.0025.006.5413.49
NVCR
^GSPC

The current NovoCure Limited Sharpe ratio is 1.58. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of NovoCure Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
1.58
2.10
NVCR (NovoCure Limited)
Benchmark (^GSPC)

Dividends

Dividend History


NovoCure Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-86.35%
-2.62%
NVCR (NovoCure Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the NovoCure Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NovoCure Limited was 95.07%, occurring on Nov 10, 2023. The portfolio has not yet recovered.

The current NovoCure Limited drawdown is 86.35%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.07%Jun 24, 2021601Nov 10, 2023
-78.83%Dec 16, 2015222Nov 1, 2016380May 8, 2018602
-45.43%Oct 4, 201834Nov 20, 201858Feb 15, 201992
-41.67%Aug 22, 2019147Mar 23, 2020122Sep 15, 2020269
-34.74%Feb 22, 202126Mar 29, 202110Apr 13, 202136

Volatility

Volatility Chart

The current NovoCure Limited volatility is 45.02%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
45.02%
3.79%
NVCR (NovoCure Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of NovoCure Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for NovoCure Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab